Apply Give

Other ways to search: Events Calendar | UTHSC

Allergy Month in Review | October 2024

Written by Communications and Marketing

|

“I am reassured by the speed of symptom relief seen in the OAS study and by the continued and consistent rapid absorption profile of Anaphylm,” Jay Lieberman, MD, a professor of medicine in the department of pediatrics at the University of Tennessee Health Science Center, said in a statement. “These data provide strong evidence that Anaphylm could provide a reliable alternative to the approved epinephrine medical devices currently available to patients.”

Top Publishers